BH Group acquires Windermere and four other hotels in UK
UK-based business property adviser Christie & Co has facilitated the sale of the properties.
The Windermere Hotel features 74 en-suite bedrooms. Amenities available at the property include two restaurant areas, a public bar, gardens, and a private car park.
The property is the inaugural hotel established in the Lake District in 1847 in Windermere.
Christie & Co local hotel agent Graham Wilkinson said: 'We are pleased to have worked with the vendors and purchasers to complete this acquisition of a significant and well-known Lake District hotel.
'It reflects the confidence in the hotel sector in Cumbria and the Lake District. BH Group pursued this hotel with vigour, and we are delighted to have reached this successful outcome. We know they have very exciting plans for this hotel.'
In addition to The Windermere, BH Group purchased the Imperial Hotel in Exmouth, the Burlington Hotel in Eastbourne, and both the St Ives Bay Hotel and Ship and Castle Hotel in Cornwall.
BH Group chief information officer James Routledge said: 'These hotels form the basis of our drive into the growing staycation market. We are excited by these opportunities and others we are currently seeing in the market.'
Christie & Co Hotels director Stephen Champion said: 'This latest transaction takes us to a total of 31 successfully completed Coast & Country sales to a wide range of buyers.'
The sale of The Windermere Hotel follows Christie & Co's recent facilitation of The Merrion Hotel in Llandudno, North Wales, which was acquired by Four Saints Hotels for an asking price of £4.5m ($6.02m).
"BH Group acquires Windermere and four other hotels in UK" was originally created and published by Hotel Management Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
26 minutes ago
- Time Business News
How Suite Possibilities Empowers Kona's Small Business Community
As Kona's local economy continues to grow, small business owners often face two common challenges: finding a professional workplace and managing back-office tasks affordably. Suite Possibilities, Kailua‑Kona, is stepping up—offering a one‑stop hub of flexible office space, administrative services, and bookkeeping solutions tailored for Hawaii's entrepreneurs and startups . Located just minutes from downtown Kona, Suite Possibilities offers office and desk rentals, conference rooms, and professional mailboxes in beautiful, fully furnished settings. Their spaces include utilities, free Wi-Fi, shared kitchens, private parking, and access to community networking—ideal for solo entrepreneurs, creatives, and itinerant business owners alike . Directory reviews consistently praise the clean, organized environment and exceptional customer service, calling out staff—especially Amanda—as 'incredibly helpful' in maintaining a welcoming atmosphere for professionals and nonprofits alike . One of Suite Possibilities' standout offerings is its range of administrative services designed to reduce overhead and free up time for business growth: Bookkeeping services , including accounts payable/receivable, payroll, reporting, and tax prep, customized for Kona-based enterprises , including accounts payable/receivable, payroll, reporting, and tax prep, customized for Kona-based enterprises Virtual receptionist support to answer calls and streamline client communications to answer calls and streamline client communications Professional mailbox rentals, enabling small business owners to maintain credibility with a branded, Kona business address—removing privacy concerns and boosting SEO visibility for Hawaii-based operations Whether hosting a client meeting or team workshop, Suite Possibilities offers flexible conference room rentals—including the Kailani and Palila rooms—that come equipped with Wi-Fi, presentation screens, coffee, seating for groups, and even ocean-view lanais. Many users value the meeting space for its professionalism and safe, Zoom-enabled capability for hybrid gatherings. Suite Possibilities was founded on the mission to 'provide an elegant, clean and creative space perfect for business travelers, local professionals, home-based businesses or club meetings'—with competitive pricing, easy accessibility, and client-focused support every step of the way . Their location just outside downtown keeps traffic low and accessibility high, adding convenience for island-based entrepreneurs. Clients like Pacific Blue Catchment LLC and Prepaid Legal Shield have credited Suite Possibilities with transforming their operations. From hosted offices to mail and bill management—from virtual receptionist support to client meeting spaces—they say the Suite's services help them streamline and focus on growth while projecting a professional image. Testimonials often highlight how Suite Possibilities operates 'like an extension of our business,' with prompt support that reflects the aloha spirit and supports scaling Kona-based small enterprises. Feature Benefit to Small Business Office & desk rentals Permanent workspace without long-term leases Conference room rentals Affordable, tech-enabled meeting spaces Professional mailboxes Honest business presence and brand credibility Bookkeeping & admin services Overhead reduced, compliance and tasks simplified Virtual receptionist Calls answered, messages filtered—uninterrupted workflow Integrated with local roots and tailored solutions, Suite Possibilities creates an ecosystem where small businesses in Kona can thrive—without drowning in administrative overhead. For ambitious small business owners or traveling professionals looking to grow their presence in Kona, Suite Possibilities offers the flexibility, professionalism, and local expertise that makes launching and thriving easier. Visit Suite Possibilities today and discover how their community-driven services can elevate your operations. Discover more at Suite Possibilities TIME BUSINESS NEWS
Yahoo
28 minutes ago
- Yahoo
Firefly Aerospace reveals target pricing as proposed IPO and stock listing date nears
Firefly Aerospace, the first commercial company to successfully land on the moon, just announced the target per-share pricing for its proposed initial public offering (IPO). The real reason a staggering 40% of U.S. homeowners are mortgage-free 5 habits that are making you a worse leader Figma's IPO date is close. The stock could trade even higher after the design startup's latest move In a filing with the U.S. Securities and Exchange Commission (SEC) today, the Texas-based company announced that it has applied to list its common stock on the Nasdaq exchange, with an offer of 16.2 million shares, each priced between $35 and $39 per share—a launch that could raise as much as $631.8 million for Firefly. The company plans to trade its stock under the ticker symbol 'FLY.' According to Firefly, net proceeds from the IPO would be used 'to repay outstanding borrowings under its credit agreement, pay any accrued and unpaid dividends on certain series of its preferred stock, and for general corporate purposes.' If the IPO is approved by the Nasdaq, it will be the latest in a series of tech-focused listings that have drawn renewed investor interest this year, a group that includes fintech company Chime, stablecoin issuer Circle, and digital health platform Hinge Health. Firefly has not disclosed a date for the listing, but said in a press release on Monday that it has launched its 'road show.' Fast Company has reached out for more information on the timing. What is Firefly Aerospace? Firefly Aerospace is a private company focusing on building small- to medium-lift launch vehicles, lunar landers, and orbital vehicles from its headquarters in Cedar Park, Texas. Its proposed IPO comes just months after the company landed on the moon for the first time through a partnership with NASA. The Blue Ghost Lunar Lander Mission 1, dubbed 'Ghost Rider in the Sky,' was a collaboration between Firefly and NASA's Commercial Lunar Payload Services (CLPS) initiative, which offers fixed contracts to commercial partners. In all, CLPS awarded Firefly $101 million to craft a four-legged lander that could deliver 10 NASA payloads (weighing 340 pounds) to the moon's surface. These payloads were designed to study topics like the behavior of lunar dust, the moon's internal structure, and the Earth's magnetosphere. The mission launched on January 15 and successfully touched down on March 2. 'It just shows that the private industry, the commercial world, has a lot of affordable, responsive technology and systems that could provide NASA a frequent means to go to the moon and carry out all these high-stakes critical-science missions for lower cost, as well as do it sustainably,' Firefly CEO Jason Kim told Fast Company in January. Currently, Firefly is gearing up to complete two more missions for NASA in 2026 and 2028. The company's success, alongside the growing prominence of other players like Elon Musk's SpaceX and Jeff Bezos's Blue Origin, shows that private companies are becoming increasingly powerful in today's space race—a trend that may make FLY stock a valuable asset to potential future investors. This post originally appeared at to get the Fast Company newsletter:
Yahoo
an hour ago
- Yahoo
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with relapsed or refractory multiple myeloma Paris, July 30, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb) targeting G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM). GPRC5D is highly expressed on plasma cells in MM patients, with low expression in healthy tissues. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. 'The orphan drug designation is a significant milestone in our ongoing efforts to develop innovative treatments in multiple myeloma,' said , Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi. 'This underscores our commitment to multiple myeloma, a disease for which we have acquired strong expertise with the development of another widely used and approved immunotherapy treatment.' The safety and efficacy of SAR446523 has not been evaluated by any regulatory authority and is still under investigation. About SAR446523SAR446523 is an investigational IgG1-based mAb designed to target GPRC5D, which is highly expressed on plasma cells, with an engineered fragment crystallizable domain to enhance antibody dependent cell-mediated cytotoxicity. This innovative approach aims to improve the efficacy of treatment for MM, a rare and challenging cancer of plasma cells. Subcutaneous SAR446523 is currently being evaluated in an ongoing phase 1, first-in-human study in patients with R/R MM (clinical study identifier: NCT06630806). SAR4465523 originates from Sanofi Research in Vitry-sur-Seine, France. About multiple myelomaMultiple myeloma is considered a rare disease, yet MM is the second most common hematologic malignancy with more than 180,000 people diagnosed with MM each year, globally. Despite available treatments, MM remains an incurable malignancy with an estimated 62% five-year survival rate for newly diagnosed patients. There is a need for new frontline therapeutic options for all patients, especially for those who are transplant ineligible, due to high attrition rates in subsequent lines of therapy. Since MM does not have a cure, most patients will relapse and stop responding to therapies they have received. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on MM clinical studies, please visit About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press Release
